A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
- Substances:–
France- Participants:18–64 years
- Sponsor:Zenas Biopharma (USA) LLC
Rare diseases
Investigational molecules
Locations
Back to France341 clinical trials in Nimes, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in FranceEssaisCliniques.fr(opens in a new tab)
France
France
France
France
France
France
France
France
France
France
France
FranceThe busiest research cities in the country
What the registry says about research in the country
Innovative trials focusing on cardiovascular conditions and metabolic disorders, examining new therapeutic approaches for heart and diabetes-related complications.
Studies evaluating novel drug combinations and monitoring strategies to improve patient outcomes.
Advanced research in cancer treatment, with particular focus on innovative therapies for various types of cancer.
Trials exploring new treatment combinations and diagnostic approaches for better patient care.
Comprehensive research into multiple sclerosis and other neurological conditions, testing innovative treatment approaches.
Focus on developing targeted therapies for various neurological conditions.
Tell us about your condition – we search every trial in Europe and connect you with the right site.